Table 2.
Comparison of the PK primary and secondary endpoints in the PK set.
| IBI301 (n = 82) | Rituximab (n = 89) | Geometric mean ratio (IBI301/rituximab) and 90% CI | |
|---|---|---|---|
| AUC0-inf (day × µg/mL) | 3,420 (978) | 3,769 (1,005) | 0.91 (0.85, 0.97) |
| AUC0-t (day × µg/mL) | 3,226 (821) | 3,534 (825) | 0.91 (0.86, 0.97) |
| Cmax (µg/mL) | 257 (58) | 266 (55) | 0.96 (0.92, 1.01) |
Data are expressed as mean ± SD.
AUC area under the curve, Cmax maximum serum concentration, PK pharmacokinetics.